Christos I. Gioumouxouzis

Dr. Christos I. Gioumouxouzis


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ioannis I. AndreadisIoannis I. Andreadis
Ioannis I. Andreadis
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
DFDimitrios Fatouros
Dimitrios Fatouros
The technological revolution has physically affected all manufacturing domains, at the gateway of the fourth industrial revolution. Three-dimensional (3D) printing has already shown its potential in this new reality, exhibiting remarkable applications in the production of drug delivery systems. As part of this concept, personalization of the dosage form by means of individualized drug dose or improved formulation functionalities has concentrated global research efforts. Beyond the manufacturing level, significant parameters must be considered to promote the real-time manufacturing of pharmaceutical products in distributed areas. The majority of current research activities is focused on formulating 3D-printed drug delivery systems while showcasing different scenarios of installing 3D printers in patients’ houses, hospitals, and community pharmacies, as well as in pharmaceutical industries. Such research presents an array of parameters that must be considered to integrate 3D printing in a future healthcare system, with special focus on regulatory issues, drug shortages, quality assurance of the product, and acceptability of these scenarios by healthcare professionals and public parties. The objective of this review is to critically present the spectrum of possible scenarios of 3D printing implementation in future healthcare and to discuss the inevitable issues that must be addressed.

1 September 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Christina KaravasiliChristina Karavasili
Christina Karavasili
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
Eleftherios AndriotisEleftherios Andriotis
Eleftherios Andriotis
DFDimitrios Fatouros
Dimitrios Fatouros

28 March 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PZPaola Zgouro
Paola Zgouro
OKOrestis L. Katsamenis
Orestis L. Katsamenis
TMThomas Moschakis
Thomas Moschakis
GEGeorgios K. Eleftheriadis
Georgios K. Eleftheriadis
AKAthanasios S. Kyriakidis
Athanasios S. Kyriakidis
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis

5 February 2026 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
CGChristos I. Gioumouxouzis
Christos I. Gioumouxouzis
Georgios EleftheriadisGeorgios Eleftheriadis
Georgios Eleftheriadis
AKAthanasios S. Kyriakidis
Athanasios S. Kyriakidis
Christina KaravasiliChristina Karavasili
Christina Karavasili
Three-dimensional printing of medicines is moving from feasibility to practice across hospital point-of-care manufacture, community-pharmacy compounding and industrial production. Recent signals include a point-of-care printed oral solid dosage form that met bioequivalence in healthy adults, automated capsule preparation with embedded checks in pharmacies and the first approved industrial product. These advances suggest that 3D printing can deliver clinically acceptable quality when responsibilities, verification and documentation are in place. This review integrates evidence across all three settings and offers a critical appraisal of what is required for safe adoption. We examine how regulatory responsibilities should be allocated across distributed sites, how non-destructive testing and chemometric models can be validated for small batches and which digital systems are essential for traceability and oversight. We analyse where economics break even compared with conventional compounding and identify use cases where 3D printing is comparatively advantaged, including low-dose titration, paediatric formats and rapid design iteration. We also outline risks that must be managed, including training and competency, cleaning validation, cross-contamination control and pharmacovigilance across networks. Finally, we propose a near-term agenda that includes standardised conduct of point-of-care trials, multi-site cost and quality benchmarking, explicit guidance on recalls and labelling and deeper industrial–clinical partnerships to turn pilots into routine practice. Graphical abstract